The High Gravity Controlled Precipitation (HGCP) technology platform is very versatile for synthesizing a wide range of different micro- and nano-sized materials. NanoMaterials Technology (NMT) offers R&D contract services to companies of pharmaceutical, biotechnological and chemical industries, who are interested in customizing their materials to the desired crystal shape & morphology, particle size & distribution, and specific physical and chemical properties.
The R&D contract service is provided in the following stages:
- Feasibility study
- NMT assesses the suitability of the HGCP platform in the synthesis of the compound of interest. At the end of the feasibility study, samples of the products will be provided to clients together with a report.
- Optimization study
- NMT will determine the optimal set of processing conditions needed for the stable and consistent production of the compound of interest. At the end of the optimization study, scalable amount samples of the products will be generated for scale-up evaluation to clients together with a report.
- Out-licensing / Contract manufacturing
- For out-licensing, NMT will design and install the HGCP technology. For contract manufacturing, NMT has existing production facilities and partners to cater to the material demand.
Our Pharmaceutical R&D Division focuses on developing micro- and nano-sized drug particles delivered by the solid oral and pulmonary inhalation routes to achieve:
- Solid oral drugs
- A reduction in particle size of poorly soluble solid oral drug will result in a substantial increase in the dissolution rate. This will not only improve the drug efficacy but also potentially reduce the drug dosage, side effects, tablet size, patience compliance, etc.
- Pulmonary inhalation drugs
- A good dispersion of inhalable drugs within the lungs depends on particle size, morphology and surface properties of the drug particles. The HGCP technology platform allows good control over these properties to design inhalable drugs with good dispersion.
The videos below show the higher fine particle fraction achievable with a small molecule pulmonary inhalation drugs (in this case, a common asthma drug salbutamol sulphate) on re-designing the drug particles